Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

Montana-Based xD Bio Inc. Receives STTR Grant for Genomic Work


WHITEFISH, Mont., Nov. 19, 2019 /PRNewswire/ -- xD Bio Inc., a privately held, Montana-based company announced today that the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has awarded the company $149,959 over 6 months for the first phase of a Small Business Technology Transfer (STTR) grant. The award supports researchers at xD Bio and collaborators at the Encyclopedia of DNA Elements (ENCODE) Data Coordinating Center (DCC) at Stanford University to demonstrate the ability to run advanced computational analyses developed by the ENCODE DCC directly through a web interface on xD Bio's web based platform, Truwl.com.

Truwl is xD Bio's flagship product that enables researchers to find, understand, use, and share computational methods for DNA sequencing data on a publicly available web-based platform. As generating large sequencing datasets becomes ubiquitous in biomedical fields, researchers depend ever more heavily on finding and implementing computational methods to make sense of the data. Making a user-friendly and centralized site for researchers to explore and collaborate on methods will remove significant barriers in the data analysis process. The development of the web interface and connected cloud compute infrastructure supported by this award is a first step to allow researchers to run analyses directly from Truwl without having to configure their own compute environments. Focusing on the thoroughly vetted, high impact methods developed by the ENCODE DCC will provide maximum value to the genomics research community.

Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R41HG010844. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For further information contact:
Karl Sebby, Ph.D.
karl.sebby@xdbio.com
406-219-8345

 

SOURCE xD Bio Inc.


These press releases may also interest you

at 11:05
Aptose Biosciences Inc. released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the Aptose management team and...

at 10:25
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen...

at 10:20
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL....

at 10:10
Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral...

at 09:35
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019...

at 09:33
Oncopeptides AB  will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with...



News published on 19 november 2019 at 17:26 and distributed by: